With our recent email about three SEP news items we've started an aggregation approach to our emails. There are no cost implications as follow.it charges a factor of the number of subscribers per day. We do this aggregation for you. Today we have three UPC-related articles to bring to your attention by way of this email -- a UPC roundup and two articles that are referenced in that roundup anyway:

1. A roundup of one of the busiest and most interesting weeks ever for the UPC.
2. CoA decision denying rehearing in Alexion cases against Amgen and Samsung Bioepis: rehearings will rarely (if ever) happen, and UPC practitioners MUST be up to date on EPO case law.
3. A highly instructive Munich LD decision on venue competence in a multi-defendant scenario involving an anchor defendant.